Chennai-Based Kriya Medical Secures Manufacturing Licence for KRIVIDA Trivus Respi Panel RT-qPCR Kit

The KRIVIDA Trivus Respi Panel RT-qPCR Kit is a unique diagnostic tool capable of simultaneously identifying Respiratory Syncytial virus (RSV), Influenza viruses, and SARS-CoV-2 from a single swab sample.

Chennai-based Kriya Medical Technologies has received manufacturing licence for its novel product, the KRIVIDA Trivus Respi Panel RT-qPCR Kit. 

The KRIVIDA Trivus Respi Panel RT-qPCR Kit is a diagnostic tool capable of simultaneously identifying Respiratory Syncytial Virus (RSV), Influenza viruses, and SARS-CoV-2 from a single swab sample. 

This kit, after validation by the ICMR-National Institute of Virology, Pune, has demonstrated a high degree of accuracy with 100% specificity and 99.11% sensitivity in detecting these three viruses.

Commenting on the development, a representative from Kriya Medical said, "The KRIVIDA Trivus Respi Panel RT-qPCR Kit is a vital breakthrough in healthcare, as it can swiftly identify RSV, a virus causing respiratory ailments in both young children and the elderly.”

The primary focus of this advanced kit is its ability to detect RSV. This virus commonly affects children under five years old, leading to viral pneumonia and a significant number of hospitalisations. 

Notably, RSV also impacts older adults, causing lower respiratory tract diseases that can lead to severe conditions including pneumonia and bronchiolitis. Hence, the early identification of RSV remains critical for both infants and the elderly.

In India, influenza contributes to about 35% of all respiratory tract infections. Severe cases of influenza can swiftly progress to acute lung injury and acute respiratory distress syndrome, resulting in high mortality rates. 

The KRIVIDA Trivus Respi Panel RT-qPCR Kit aids in the timely detection of influenza, facilitating the prompt initiation of specific antiviral medications.

Furthermore, the kit's capability to detect co-infections is significant, as these co-infections often lead to more severe diseases, increased morbidity, and mortality due to compromised immune systems. Therefore, this innovative medical tool is a valuable asset in enhancing diagnostic capabilities and infection control measures.

Kriya Medical Technologies, a medical device company established in 2006, aims to bring advanced healthcare technologies to the expanding Indian market.
Previously, the ICMR had approved KRIVIDA TRIVUS to detect Influenza, SARS CoV2, and Respiratory Syncytial Virus. This kit detects influenza (H1N1, H3N2, Yamagata, and Victoria sublines), SARS CoV2, and Respiratory Syncytial Virus (RSV) with RT-qPCR.

In the world of medical technology innovation, recently, Supriya Lifescience, a Mumbai-based pharmaceutical company, has collaborated with the Kalinga Institute of Industrial Technology (KIIT) to introduce a cost-effective oral cancer detection kit named "Quickblue."

The Quickblue oral cancer detection kit is designed to enhance oral cancer diagnosis, providing a faster and more economical alternative to traditional biopsy methods.